Antihyperglycemic Potential of Incretins Orally Delivered via Nano and Microsystems and Subsequent Glucoregulatory Effects

• Type: Article in International Scientific Journal
• Date: 2014

Authors

Francisca Araujo (Author) Other; Neha Shrestha (Author) Other; Pedro L Granja (Author) FEUP; Jouni Hirvonen (Author) Other; Helder A Santos (Author) Other; Bruno Sarmento (Author) Other

Journal

Title: Current Pharmaceutical Biotechnology

Vol. 15

Pages: 609-619

ISSN: 1389-2010

Publisher: Bentham Science

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Scientific classification

FOS: Medical and Health sciences > Basic medicine

Other information

Authenticus ID: P-009-V6A

Abstract (EN): Type 2 diabetes mellitus (T2DM) is mainly associated with impaired insulin secretion by the pancreatic beta-cells, insulin resistance and elevated hepatic gluconeogenesis. Incretin based treatments for T2DM are now widely investigated and used. The incretin based therapies mainly include incretin hormones which are glucose-dependent insulinotropic peptides (GIP) and glucagon like peptide-1 (GLP-1) released from the endocrinal cells in the small intestine in response to food intake. The main function of GLP-1 is to induce insulin secretion and suppress glucagon secretion. This review describes the different formulation approaches for oral delivery of incretins and the limitations associated with this route of administration. We highlight the use of micro and nanosystems to efficiently deliver the incretins orally. Furthermore, we present several examples of the significant potential of these systems in pharmaceutical applications.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 11